Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 5:11 AM
Ignite Modification Date:
2025-12-25 @ 5:11 AM
NCT ID:
NCT04266327
Eligibility Criteria:
Inclusion Criteria:
* (1) age 18-75 years
* (2) the lesion was located at the thoracic entrance, pathologically diagnosed as lymph node metastatic squamous cell carcinoma, and relapsed after radiotherapy. The diameter of the lesion was ≤5cm
* (3) no systemic metastasis or metastasis, the metastasis has been controlled by early treatment
* (4) no bleeding tendency, anticoagulant treatment and (or) anti-platelet coagulation drugs should be at least 1 week before the seed implantation treatment
* (5) not complicated with serious or uncontrolled basic diseases (such as serious or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, etc.)
* (6) there is a suitable puncture path, is expected to reach the treatment dose;7 KPS\> score of 70, expected to be able to tolerate puncture/particle therapy, the expected survival time is more than 3 months
Exclusion Criteria:
* (1) extensive invasion of the lesion or surrounding of large blood vessels or large scope of liquefaction necrosis inside the lesion, high risk of expected puncture bleeding or poor particle distribution
* (2) puncture site infection and/or ulcer
* (3) pregnant women, nursing women, children and mental patients
* (4) patients who are participating in other clinical studies
* (5) poor compliance, unable to complete the treatment
* (6) the researchers consider it inappropriate to participate in the clinical trial
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT04266327
Study Brief:
Protocol Section:
NCT04266327